PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy
Author:
Affiliation:
1. Department of Radiology; Brigham and Women's Hospital and Dana-Farber Cancer Institute; Boston MA USA
2. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA
Funder
National Cancer Institute
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14441/fullpdf
Reference9 articles.
1. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;New England Journal of Medicine,2015
2. Overall survival and long-term safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer;Gettinger;Journal of Clinical Oncology,2015
3. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant;Lane;Leukaemia & Lymphoma,2012
4. Anti-PD-1-related pneumonitis during cancer immunotherapy;Nishino;New England Journal of Medicine,2015a
5. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenstrom Macroglobulinemia as a Paradigm;Nishino;Oncologist,2015b
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report;World Journal of Gastrointestinal Oncology;2023-05-15
2. Immune check‐point inhibitor‐related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease;Histopathology;2022-08-17
3. Progressive Pulmonary Infiltrates in a Man with Mediastinal Lymphoma;Annals of the American Thoracic Society;2021-05
4. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy;Lung;2021-02-22
5. Analysis of clinical effect of PD-1 inhibitor combined with chemotherapy in the treatment of nasal type NK/T cell lymphoma;Panminerva Medica;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3